Article
Pharma major Novartis falls nearly 10%, heading for worst day on record after three drug trial setbacks
Pessimistic
-47.0
−100 Bearish
0
+100 Bullish
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Pessimistic
-47.0
−100Neutral+100
More Like This